Biotechnology – Talk Bio

Shankar Ramaswamy’s Kriya Therapeutics Raises $313M for Gene Therapy Advancements

4 days ago talkbio0Tagged Biotechnology, gene therapy, Kriya, Shankar Ramaswamy, venture

Kriya Therapeutics; Shankar Ramaswamy; gene therapy; biotech funding; fundraising; biotechnology; venture capital; 2025

Moderna to Cut 10% of Workforce in $1.5B Cost-Saving Push

3 weeks ago talkbio0Tagged Biotechnology, COVID-19 Vaccines, Financial savings, layoffs, Moderna, Stéphane Bancel

Moderna; layoffs; workforce reduction; cost-cutting; $1.5 billion savings; 2025; Stéphane Bancel; biotechnology; COVID-19 vaccine

Biogen Pledges $2 Billion Manufacturing Investment in North Carolina

1 month ago talkbio0Tagged Antisense Oligonucleotides, Aortic Valve Insufficiency, Automation, Biogen, Biotechnology, expansion, gene therapy, Investments, Manufacturing, North Carolina, Research Triangle Park

Biogen; manufacturing investment; North Carolina; Research Triangle Park; biotechnology; antisense oligonucleotides; gene therapy; automation; AI; expansion

Illumina Acquires SomaLogic to Accelerate Proteomics Strategy with $350M Upfront

2 months ago talkbio0Tagged Acquisition, Biotechnology, Illumina, Proteomics, SomaLogic, Standard BioTools

Illumina; SomaLogic; Standard BioTools; proteomics; acquisition; biotechnology

Inside the FDA’s Listening Tour: Officials Agree US Lags Behind China on Drug Development

2 months ago talkbio0Tagged Biotechnology, China, Clinical Trials, Drug Development, Drug Industry, innovation, Regulation, United States Food and Drug Administration

FDA; China; drug development; biotechnology; regulation; clinical trials; pharmaceutical industry; biotech innovation

Genentech’s Kristin Bittenbender Named BIO Board Chair Amid Industry Challenges

2 months ago talkbio0Tagged Bio, biotech industry, Biotechnology, board chair, existential threats, genentech, Kristin Bittenbender, Leadership Change, Policy, United States Food and Drug Administration

BIO; Genentech; Kristin Bittenbender; board chair; biotech industry; FDA; existential threats; leadership change; biotechnology policy

BioNTech to Acquire CureVac in $1.25B All-Stock mRNA Deal

2 months ago talkbio0Tagged Acquisition, all-stock, BioNTech, Biotechnology, Cancer Therapeutic Procedure, COVID-19 Vaccines, CureVac, Germany, mRNA Vaccines, Neoplasms

BioNTech; CureVac; acquisition; mRNA vaccines; cancer treatment; all-stock deal; Germany; biotechnology; oncology; COVID-19 vaccine

Recent Developments in Building Robust Health System Partnerships for Life Sciences (2025)

3 months ago talkbio0Tagged Artificial Intelligence, Biological Science Disciplines, Biotechnology, Computer Security, Data Integration, digital transformation, health system partnerships, Primary Health Care, Salesforce Life Sciences Cloud, strategic partnerships

health system partnerships; life sciences; strategic partnerships; digital transformation; artificial intelligence; cybersecurity; primary care; biotechnology; Salesforce Life Sciences Cloud; data integration

Ironwood Pharmaceuticals’ Stock Plummets Following Layoffs and FDA Setback for Apraglutide

4 months ago talkbio0Tagged Biotechnology, Goldman Sachs, Ironwood, Phase 3 Clinical Trials, plunge, regulatory hurdle, Short Bowel Syndrome, strategic alternatives, United States Food and Drug Administration

Ironwood Pharmaceuticals , apraglutide , short bowel syndrome (SBS) , Phase III trial , layoffs , FDA regulatory hurdle , stock plunge , strategic alternatives , Goldman Sachs , biotechnology

Navigating Challenges: Keros and Tempest Aim to Stabilize and Strategize for Growth

4 months ago talkbio0Tagged biopharmaceutical sector, Biotechnology, Clinical Trials, Corporate, financial, Infantile Neuroaxonal Dystrophy, Investments, restructuring, stockholder, strategic alternatives

Keros Therapeutics , Strategic alternatives , Financial challenges , Biopharmaceutical sector , Stockholder rights plan , Clinical trials , Tempest Therapeutics , Corporate restructuring , Biotechnology investments